Is Gland Pharma overvalued or undervalued?

As of 7 November 2025, Gland Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its relative valuation. However, the company remains overvalued. Key ratios reveal a PE Ratio of 38.88, an EV to EBITDA of 4.16, and a PEG Ratio of 2.72, which are relatively high compared to its peers.
In comparison, Sun Pharma has a PE Ratio of 35.17 and an EV to EBITDA of 10.65, while Cipla stands out with a more attractive PE Ratio of 22.33 and an EV to EBITDA of 5.58. Gland Pharma's current price of 1865.00 reflects a decline in stock performance over the past month, contrasting with the Sensex's positive return of 1.57%. Overall, Gland Pharma's valuation metrics suggest that it is overvalued in the current market context.